EMBC — Embecta Corp.

Summary of Embecta Corp. Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 2025 Revenue: $264 million, a decline of 7.7% year-over-year (10.4% decline on an adjusted constant currency basis).
• US Revenue: $142 million, down 15.2% (adjusted constant currency).
• International Revenue: $122 million, up 2.8% (down 4% adjusted constant currency).
• Full Year 2025 Revenue: Approximately $1.08 billion, a 3.9% decline (adjusted constant currency).
• Adjusted Gross Profit Margin: 60.6% in Q4 and 63.7% for the full year, down from 61.4% and 65.7% respectively in the prior year.
• Adjusted Operating Income Margin: 25.3% in Q4 and 31.3% for the full year, up from 21.1% and 26.3% respectively.
• Adjusted Diluted EPS: $2.95 for the full year, up from $2.45 in the prior year.
• Free Cash Flow: Approximately $182 million generated in 2025, with $184 million of debt repaid.

2. Strategic Updates and Business Highlights:

• Operational Improvements: Completed ERP implementation and exited all transitional service agreements (TSAs) and license agreements (LSAs) from the spin-off.
• Brand Transition: Over 95% of North American revenue transitioned to the new brand, with global initiatives expected to complete by the end of 2026.
• GLP-1 Strategy: Collaborating with over 30 pharmaceutical partners for co-packaging pen needles with generic GLP-1 therapies, with anticipated launches in Canada, Brazil, and India in 2026.
• Product Development: Initiated new programs for market-appropriate syringes and pen needles to expand market reach.

3. Forward Guidance and Outlook:

• Fiscal 2026 Revenue Guidance: Expected to be flat to down 2% compared to 2025, with a range of $1.071 billion to $1.093 billion.
• Adjusted Operating Margin Guidance: Expected to be between 29-30%, reflecting a decline due to increased cannula costs and anticipated R&D investments.
• Adjusted EPS Guidance: Projected range of $2.80 to $3.00.
• Free Cash Flow Expectations for 2026: Anticipated to be between $180 million and $200 million.

4. Bad News, Challenges, or Points of Concern:

• Revenue Declines: Notable declines in both US and international revenues, particularly impacted by prior year inventory dynamics and competitive pressures in China.
• Cannula Cost Increases: Sole sourcing from BD has led to increased costs, affecting gross margins.
• Geopolitical Pressures: Ongoing challenges in China due to competitive intensity and changing consumer preferences, which may affect future revenue.
• Market Dynamics: Declining volumes in core injection products, particularly syringes, as insulin vial prescriptions decrease.

5. Notable Q&A Insights:

• GLP-1 Partnerships: Over 30 partners are engaged, with some already placing orders. However, revenue from these partnerships is not included in the 2026 guidance due to uncertainty in regulatory approval timelines.
• China Market Dynamics: The company has reorganized its sales team and introduced a more competitively priced pen needle to stabilize performance in China.
• Cannula Supply Strategy: Efforts are underway to identify alternative suppliers to mitigate cost pressures from sole sourcing.
• Intellectual Property Sale: A $10 million sale of assets related to the discontinued patch pump program is expected to enhance cash flow but will not impact adjusted financial results.

Overall, Embecta Corp. demonstrated solid execution in 2025 with strategic initiatives aimed at long-term growth, despite facing revenue declines and market challenges. The company remains focused on maintaining profitability and cash flow while navigating a complex market landscape.